Abeona Therapeutics (ABEO) Liabilities and Shareholders Equity (2010 - 2026)

Abeona Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $198.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 99.76% year-over-year to $198.5 million; the TTM figure through Mar 2026 stood at $895.4 million (up 93.44% YoY), while the FY2025 annual figure was $219.6 million, up 101.57% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $198.5 million, down from $219.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $246.2 million in Q2 2025, with the low at $38.8 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $74.8 million (2024), against an average of $110.2 million.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity sank 67.43% in 2022, then jumped 150.24% in 2024.
• Abeona Therapeutics' Liabilities and Shareholders Equity stood at $64.2 million in 2022, then declined by 0.33% to $64.0 million in 2023, then surged by 70.2% to $108.9 million in 2024, then surged by 101.57% to $219.6 million in 2025, then decreased by 9.6% to $198.5 million in 2026.
• Business Quant data shows ABEO's Liabilities and Shareholders Equity at $198.5 million in Q1 2026, $219.6 million in Q4 2025, and $231.1 million in Q3 2025.